deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT01345136

Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma

A Single Arm, Monocenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma

Sponsor: Jonsson Comprehensive Cancer Center

Conditions Neurofibromatosis Type 2 Neuroma, Acoustic
Interventions RAD001, everolimus
Updated 13 times since 2017 Last updated: Feb 9, 2024 Started: Jul 1, 2015 Primary completion: Feb 6, 2024 Completion: Feb 6, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

slow accrual

Other terminated trials from Jonsson Comprehensive Cancer Center

See all terminations from Jonsson Comprehensive Cancer Center

Listed as NCT01345136, this PHASE2 trial focuses on Neurofibromatosis Type 2 and Neuroma, Acoustic and remains terminated or withdrawn. Sponsored by Jonsson Comprehensive Cancer Center, it has been updated 13 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Dec 2017 · 10 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Mar 2020 · 12 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Apr 2022 · 12 months · monthly snapshot~Apr 2022 – ~Mar 2023 · 11 months · monthly snapshot~Mar 2023 – ~Mar 2024 · 12 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Mar 2024 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  4. Mar 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Apr 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2

▶ Show 8 earlier versions

  1. Apr 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Mar 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Mar 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE2

  5. Jun 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

  6. Dec 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Feb 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  8. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Jonsson Comprehensive Cancer Center
  • Novartis Pharmaceuticals
Data source: Jonsson Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations